NCT05228496 2023-09-26A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLCZhejiang Cancer HospitalPhase 2 Unknown21 enrolled
NCT04620837 2020-11-09Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line ChemotherapyChineseAMSPhase 2 Unknown25 enrolled